This report provides a comprehensive review of 27 candidate therapeutic antibodies that are being evaluated for the treatment of lung cancer; covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 potential targets.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of lung cancer on society drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required
Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations, and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report (see brochure) provides a comprehensive review of lung cancer therapeutic antibodies and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.
Today, more than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field.
Key content:
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of lung cancer on society drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required
Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations, and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report (see brochure) provides a comprehensive review of lung cancer therapeutic antibodies and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.
Today, more than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field.
Key content:
- Late-stage (Phases 2/3, 3 and Approved, n = 4) pipeline therapeutic antibodies and companies
- Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) pipeline therapeutic antibodies and companies
- Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
- Drug targets being targeted by therapeutic antibodies from preclinical through to Phase 3, and Approved
- Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer
- Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer
- Commercial partnerships and collaborations on pipeline therapeutic antibodies
- Drug combination strategies in the evaluation of therapeutic antibodies for the targeting of lung cancer
- A comprehensive listing of salient details of clinical trials of therapeutic antibodies being evaluated for the treatment of lung cancer
- Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies for the treatment of lung cancer
- Competitive and market-related information
EXECUTIVE SUMMARY
CHAPTER 1 BACKGROUND
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
References
CHAPTER 2 APPROVED AND LATE-STAGE THERAPEUTIC ANTIBODIES
Summary
2.1 Introduction
2.2 Overview
2.3 (One antibody, Approved)
2.4 – 2.6 (Three antibodies, Phase 3)
References
CHAPTER 3 EARLY-STAGE THERAPEUTIC ANTIBODIES
Summary
3.1 Introduction
3.2 Overview
3.3 – 4.12 (Ten antibodies, Phase 2)
3.13 – 4.18 (Six antibodies, Phase 1/2)
3.19 – 4.23 (Five antibodies, Phase 1)
4.24 – 4.25 (Two antibodies, Preclinical)
References
CHAPTER 4 OTHER CANDIDATE THERAPIES
Summary
4.1 Introduction
4.2 Overview
4.3 (One Immune Activator, Phase 2)
4.4 (One Antibody Conjugate, Phase 1/2)
4.5 (One Bispecific Antibody, Phase 1)
4.6 (One Antibody Conjugate, Phase 1)
4.7 (One Immune Stimulant, Phase 1)
4.8 (One Antibody Conjugate, Phase 1)
References
CHAPTER 5 DISCUSSION
5.1 Background
5.2 Pipeline
5.3 Therapeutic Antibodies
5.4 Other Candidate Therapies
5.5 Companies
5.6 Therapeutic Targets
5.7 Therapeutic Approaches
References
TABLES
1.1 Global incidence and mortality from lung cancer, 2008
1.2 NSCLC survival rates, according to cancer stage
1.3a Five-year relative cancer survival rates in the USA for white males
1.3b Five-year relative cancer survival rates in the USA for white females
1.4 US national expenditure on different cancers (2006)
1.5 US lost productivity due to different cancer types in the US, 2005
2.1 Approved/late-stage candidate therapeutic antibodies for the treatment of lung cancer
3.1 Early-stage therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
5.1 Approved/late-stage therapeutic antibodies being developed for the treatment of lung cancer
5.2 Early-stage candidate therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
5.3 Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
5.4 Approved/candidate therapeutic antibodies for the treatment of lung cancer or for lung cancer/other cancers
5.5 Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for lung cancer/other cancers
5.6 NSCLC survival rates, according to cancer stage
FIGURES
3.1 Early-stage pipeline therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers
5.4 Approved and pipeline therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung/other cancers
5.6 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
5.10 Organisations developing or evaluating lung cancer therapeutic antibodies
5.12 Clinical trials of therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents
CHAPTER 1 BACKGROUND
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
References
CHAPTER 2 APPROVED AND LATE-STAGE THERAPEUTIC ANTIBODIES
Summary
2.1 Introduction
2.2 Overview
2.3 (One antibody, Approved)
2.4 – 2.6 (Three antibodies, Phase 3)
References
CHAPTER 3 EARLY-STAGE THERAPEUTIC ANTIBODIES
Summary
3.1 Introduction
3.2 Overview
3.3 – 4.12 (Ten antibodies, Phase 2)
3.13 – 4.18 (Six antibodies, Phase 1/2)
3.19 – 4.23 (Five antibodies, Phase 1)
4.24 – 4.25 (Two antibodies, Preclinical)
References
CHAPTER 4 OTHER CANDIDATE THERAPIES
Summary
4.1 Introduction
4.2 Overview
4.3 (One Immune Activator, Phase 2)
4.4 (One Antibody Conjugate, Phase 1/2)
4.5 (One Bispecific Antibody, Phase 1)
4.6 (One Antibody Conjugate, Phase 1)
4.7 (One Immune Stimulant, Phase 1)
4.8 (One Antibody Conjugate, Phase 1)
References
CHAPTER 5 DISCUSSION
5.1 Background
5.2 Pipeline
5.3 Therapeutic Antibodies
5.4 Other Candidate Therapies
5.5 Companies
5.6 Therapeutic Targets
5.7 Therapeutic Approaches
References
TABLES
1.1 Global incidence and mortality from lung cancer, 2008
1.2 NSCLC survival rates, according to cancer stage
1.3a Five-year relative cancer survival rates in the USA for white males
1.3b Five-year relative cancer survival rates in the USA for white females
1.4 US national expenditure on different cancers (2006)
1.5 US lost productivity due to different cancer types in the US, 2005
2.1 Approved/late-stage candidate therapeutic antibodies for the treatment of lung cancer
3.1 Early-stage therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
5.1 Approved/late-stage therapeutic antibodies being developed for the treatment of lung cancer
5.2 Early-stage candidate therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
5.3 Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
5.4 Approved/candidate therapeutic antibodies for the treatment of lung cancer or for lung cancer/other cancers
5.5 Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for lung cancer/other cancers
5.6 NSCLC survival rates, according to cancer stage
FIGURES
3.1 Early-stage pipeline therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers
5.4 Approved and pipeline therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung/other cancers
5.6 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
5.10 Organisations developing or evaluating lung cancer therapeutic antibodies
5.12 Clinical trials of therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents
